Eric Ende

Dr. Ende was a Director on Genzyme’s Board from 2010 – 2011 until it was acquired by Sanofi-Aventis in 2011 for $20 billion. During his tenure on Genzyme’s Board, he was a member of the Audit and Risk Management Committees.

Ende is currently serving on the Technology Transfer Committee that oversees Mount Sinai Innovation Partners of the Mount Sinai Health System. He is also serving on the Scientific Advisory Board of Noble Life Science Partners of Noble Financial Capital Markets, an investment and merchant banking firm. Ende is currently studying to obtain an American College of Sports Medicine (ACSM) certification – ACSM Certified Group Instructor.

Since 2008, Ende has served as a managing partner of multiple real estate investment companies that purchase, stabilize and rent retail stores in commercial shopping centers.

From 2002 through 2008, Dr. Ende was the senior biotechnology analyst at Merrill Lynch. From 2000 – 2002, Ende was the senior biotechnology analyst at Banc of America Securities. And, from 1997 – 2000, he was a biotechnology analyst at Lehman Brothers. During Dr. Ende’s career as a biotechnology analyst, he was named to Institutional Investor’s All-America Equity Research Team six times as well as to The Greenwich Survey list of top analysts. He was also named Top Stock Picker by The Street.com and Best Earnings Estimator by Forbes.com. Dr. Ende received an MBA in Finance & Accounting from NYU – Stern Business School in 1997, an MD from Mount Sinai School of Medicine in 1994, and a BS in Biology and Psychology from Emory University in 1990.